Dyadic International Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -90.6% over 5Y.
today you would have $74.82▼ -92.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.94 | $1.75 | $1.61 | $1.23 | $4.52 | $5.38 | $5.18 | $1.89 | $1.39 | |
| P/S | 39.0x | 11.1x | 15.1x | 16.1x | 12.1x | 53.1x | 92.5x | 84.3x | 39.0x | 51.9x |
| P/B | 5.2x | 27.8x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TVRDTvardi Therapeutics, Inc. | $1.82 | — | 1.2x | — | -126.19% | $24.28M |
| TXMDTherapeuticsMD, Inc. | $2.16 | — | 0.9x | — | -1.08% | $25M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| EVAXEvaxion A/S | $3.01 |
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Company description provided by Yahoo Finance.
| 21.3x |
| 7.9x |
| 3.2x |
| 6.9x |
| 5.2x |
| 4.0x |
| 1.2x |
| 0.8x |
| EPS | -$0.23 | -$0.20 | -$0.24 | -$0.34 | -$0.47 | -$0.34 | -$0.31 | -$0.21 | -$0.07 |
| Profit margin | -332.23% | -238.31% | -166.19% | -234.42% | -332.23% | -543.73% | -582.13% | -494.21% | -439.36% | -281.61% |
| ROE | -71.07% | -597.58% | -235.16% | -115.60% | -87.80% | -71.07% | -32.78% | -23.16% | -13.41% | -4.27% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.4x |
| — |
| -109.86% |
| $25.1M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |